Prevention of the development of catheterassociated urinary system infections in the early postoperative period
- Authors: Al-Shukri A.S.1, Maksimova A.V.1, Dub N.I.2, Kostyukov S.V.1, Manchenko A.A.1, Ponomareva Y.A.1, Mayorov I.D.3, Petrov S.B.1
-
Affiliations:
- FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
- FGBVOU VO S.M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation
- FGBU NMRC named after V.A. Almazov of the Ministry of Health of the Russian Federation
- Issue: No 2 (2023)
- Pages: 13-19
- Section: Original Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/520800
- DOI: https://doi.org/10.18565/urology.2023.2.13-19
- ID: 520800
Cite item
Open Access
Access granted
Abstract
Background. Bladder catheterization is a common medical manipulation that is associated with the risk of complications, including catheter-associated urinary tract infection (CAUTI), which accounts for 80% of all nosocomial infections of the urological profile. Aim. To evaluate the combined use of the biologically active additive Uronext and ceftriaxone in the prevention of the development of CAUTI in the early postoperative period in 120 patients aged 20–80 years with a Foley indwelling catheter.
Materials and methods: The patients were divided into 2 groups: in group I (n=60), D-mannose with cranberry extract and vitamin D3 as part of Uronext dietary supplement was administered orally in the form of sachets 48 hours before surgery and after surgery until urethral catheter was placed, as well as intravenous ceftriaxone 1000 mg 2 hours before surgery and in the postoperative period within 7 days. In group II (n=60), ceftriaxone monotherapy was prescribed in a similar way.
Results: According to the results of bacteriological examination of the removed urinary catheter on 3–7 days in Uronext group, bacterial growth was absent in 40 patients (66.67%, p<0.05), versus 23 cases (38.33%) in the control group.
Conclusions: The data obtained confirm the efficiency of the use of the biologically active additive Uronext in combination with an antibacterial drug, which allows to recommend this scheme in patients with an indwelling urinary catheter for the prevention of the development of CAUTI.
Full Text
About the authors
A. S. Al-Shukri
FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
Author for correspondence.
Email: ad330@mail.ru
ORCID iD: 0000-0001-6543-8589
Scopus Author ID: 28367540300
Ph.D., MD, professor, Head of the Urological Department No1 (general and emergent urology) of Scientific and Research Center of Urology of Scientific and Research Institute of Surgery and Emergent Medicine
Russian Federation, Saint PetersburgA. V. Maksimova
FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
Email: maksimova_av77@mail.ru
ORCID iD: 0000-0002-5627-2596
student
Russian Federation, Saint PetersburgN. I. Dub
FGBVOU VO S.M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation
Email: dubnikita1998@gmail.com
ORCID iD: 0000-0002-4049-4178
student
Russian Federation, Saint PetersburgS. V. Kostyukov
FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
Email: kostyukov57@mail.ru
ORCID iD: 0000-0003-3176-716X
urologist at the Department of Urology
Russian Federation, Saint PetersburgA. A. Manchenko
FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
Email: manchenko_9797@mail.ru
ORCID iD: 0000-0002-7671-905X
urologist at the Department of Urology
Russian Federation, Saint PetersburgYu. A. Ponomareva
FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
Email: uaponomareva@mail.ru
ORCID iD: 0000-0003-3492-4220
Ph.D., Head of Urological Department No1 of Scientific and Research Center of Urology of Scientific and Research Institute of Surgery and Emergent Medicine
Russian Federation, Saint PetersburgI. D. Mayorov
FGBU NMRC named after V.A. Almazov of the Ministry of Health of the Russian Federation
Email: ilmayorov@ya.ru
ORCID iD: 0000-0003-3142-6488
resident in urology
Russian Federation, Saint PetersburgS. B. Petrov
FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
Email: petrov@urology.spb.ru
ORCID iD: 0000-0003-3460-3427
Ph.D., MD, professor, Head of the Scientific and Research Center of Urology of Scientific and Research Institute of Surgery and Emergent Medicine
Russian Federation, Saint PetersburgReferences
- Kranz J., Schmidt S., Wagenlehner F., Schneidewind L. Catheter-Associated Urinary Tract Infections in Adult Patients. Dtsch Arztebl Int. 2020;117(6):83–88. doi: 10.3238/arztebl.2020.0083.
- Mangal S., Pho A., Arcia A., Carter E. Patient and Family Engagement in Catheter-Associated Urinary Tract Infection (CAUTI) Prevention: A Systematic Review. Jt Comm J Qual Patient Saf. 2021.
- Vinnik Yu.S. et al. Features of the formation of microbial biofilms on various substrates. The possibility of studying biofilms on bile concretions. Modern problems of science and education. 2013;5:323–323.
- Flores-Mireles A., Hreha T.N., Hunstad D.A. Pathophysiology, Treatment, and Prevention of Catheter-Associated Urinary Tract Infection. Top Spinal Cord Inj Rehabil. 2019;25(3):228–240. doi: 10.1310/sci2503-228.
- Zaitsev A.V. et al. Biofilm control in urological practice. Urology. 2022;1:81–88. Doi: https://dx.doi.org/10.18565/urology.2022.1.81-88.
- Parsons C.L. Pathogenesis of urinary tract infections: bacterial adherence, bladder defense mechanisms. Urol Clin North Am. 1986;13(4):563–568. doi: 10.1016/S0094-0143(21)00262-7.
- Shuman E.K., Chenoweth C.E. Urinary catheter-associated infections. Infectious Disease Clinics. 2018;32(4):885–897.
- Yin W., Wang Y., Liu L., He J. Biofilms: The Microbial «Protective Clothing» in Extreme Environments. Int J Mol Sci. 2019;20(14):3423. doi: 10.3390/ijms20143423.
- Boopathi S., Ramasamy S., Haridevamuthu B., et al. Intercellular communication and social behaviors in mycobacteria. Front Microbiol. 2022;13:943278. doi: 10.3389/fmicb.2022.943278.
- Chuang L., Tambyah P.A. Catheter-associated urinary tract infection. J Infect Chemother. 2021;27(10):1400–1406. doi: 10.1016/j.jiac.2021.07.022
- Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–284. doi: 10.1038/nrmicro3432.
- Slesarevskaya M.N., Al-Shukri S.H., Kuzmin I.V., et al. Nosocomial infections in a urological hospital. Urological reports. 2019;9(5):85–88.
- Lo Evelyn, et al. Strategies to Prevent Catheter-Associated Urinary Tract Infections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology. 2014;35(5):464–479. JSTOR, https://doi.org/10.1086/675718
- Mangal S., Pho A., Arcia A., Carter E. Patient and Family Engagement in Catheter-Associated Urinary Tract Infection (CAUTI) Prevention: A Systematic Review. Jt Comm J Qual Patient Saf. 2021;47(9):591–603. doi: 10.1016/j.jcjq.2021.05.009.
- Hakvoort R.A., Burger M.P., Emanuel M.H., Roovers J.P. A nationwide survey to measure practice variation of catheterisation management in patients undergoing vaginal prolapse surgery. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(7):813–818. doi: 10.1007/s00192-009-0847-4.
- Singha P., Locklin J., Handa H. A review of the recent advances in antimicrobial coatings for urinary catheters. Acta Biomater. 2017;50:20–40. doi: 10.1016/j.actbio.2016.11.070.
- Zhang S., Liang X., Gadd G.M., Zhao Q. Marine Microbial-Derived Antibiotics and Biosurfactants as Potential New Agents against Catheter-Associated Urinary Tract Infections. Mar Drugs. 2021;19(5):255. doi: 10.3390/md19050255.
- Perepanova T.S. The 2015 Federal Clinical Guidelines for Antimicrobial Therapy and Prevention of Infections of the Kidney, Urinary Tract, and Male Genitals. Ter Arkh [Internet]. 2016 [cited 2022 Oct 8];88(4):100–104. Available from: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/terapevticheskiy-arkhiv/ta2016/ta2016_4/federalnye-klinicheskie-rekomendatsii-antimikrobnaya-terapiya-i-profilaktika-infektsiy-pochek-mochev/
- Ala-Jaakkola R., Laitila A., Ouwehand A.C., Lehtoranta L. Role of D-mannose in urinary tract infections – a narrative review. Nutr J. 2022;21(1):18. doi: 10.1186/s12937-022-00769-x
- Nemzer B.V., Al-Taher F., Yashin A., Revelsky I., Yashin Y. Cranberry: Chemical Composition, Antioxidant Activity and Impact on Human Health: Overview. Molecules. 2022;27(5):1503. doi: 10.3390/molecules27051503.
- Hsueh P.R., Hoban D.J., Carmeli Y., Chen S.Y., Desikan S., Alejandria M., et al. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect [Internet]. 2011 Aug [cited 2022 Oct 8];63(2):114–123. Available from: https://pubmed.ncbi.nlm.nih.gov/21669223/
- Liu X., Sai F., Li L., Zhu C., Huang H. Clinical characteristics and risk factors of catheter-associated urinary tract infections caused by Klebsiella Pneumoniae. Ann Palliat Med [Internet]. 2020 Sep 1 [cited 2022 Oct 8];9(5):2668–2677. Available from: https://pubmed.ncbi.nlm.nih.gov/32921093/
- Barbadoro P., Labricciosa F.M., Recanatini C., Gori G., Tirabassi F., Martini E., et al. Catheter-associated urinary tract infection: Role of the setting of catheter insertion. Am J Infect Control [Internet]. 2015 Jul 1 [cited 2022 Oct 8];43(7):707–710. Available from: https://pubmed.ncbi.nlm.nih.gov/25840715/
- Abisado R.G., Benomar S., Klaus J.R., Dandekar A.A., Chandler J.R. Bacterial Quorum Sensing and Microbial Community Interactions. mBio [Internet]. 2018 May 1 [cited 2022 Oct 9];9(3). Available from: /pmc/articles/PMC5964356/
- Lenger S.M., Bradley M.S., Thomas D.A., Bertolet M.H., Lowder J.L., Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol [Internet]. 2020 Aug 1 [cited 2022 Oct 9];223(2):265.e1. Available from: /pmc/articles/PMC7395894/
- Kranjčec B., Papeš D., Altarac S. d-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World Journal of Urology 2013 32:1 [Internet]. 2013 Apr 30 [cited 2022 Oct 10];32(1):79–84. Available from: https://link.springer.com/article/10.1007/s00345-013-1091-6
- Fu Z., Liska D., Talan D., Chung M. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr. 2017;147(12):2282–2288. doi: 10.3945/jn.117.254961.
- Esipov A.V., Alechnovich A.V., Markevich P.S., Kislenko A.M., Zaytsev A.V. The role of biofilms in the pathogenesis of catheter-associated urinary tract infections. Hospital medicine: science and practice. 2021; 4(1):26–30.
- Köves B., Magyar A., Tenke P. Spectrum and antibiotic resistance of catheter-associated urinary tract infections. GMS Infect Dis [Internet]. 2017 [cited 2022 Oct 8];5:Doc06. Available from: /pmc/articles/PMC6301742/
- Baron G., Altomare A., Regazzoni L., et al. Profiling Vaccinium macrocarpon components and metabolites in human urine and the urine ex-vivo effect on Candida albicans adhesion and biofilm-formation. Biochem Pharmacol. 2020;173:113726. doi: 10.1016/j.bcp.2019.113726.
Supplementary files
